EDEN PRAIRIE, Minn., Dec. 15, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced ...
Tirzepatide significantly reduces cardiovascular death or worsening heart failure risk by 38% in patients with obesity-related HFpEF. The drug improves blood pressure, inflammation, and volume ...
Please provide your email address to receive an email when new articles are posted on . Patients with chronic kidney disease and fluid overload are at risk for cardiovascular events and kidney disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results